Biostax Corp.
DelistedCIK 1559356fmd_0T5ZD0B9DB8ZJVES0NBK76D7VRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Jun 30, 2024, 52 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | – | 0 | – | – | – | – | – |
| Cost of revenue | – | – | – | – | 0 | – | – | – | – | – |
| Gross profit | – | – | – | – | 0 | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | – | 6 | – | – |
| Research and development | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 4 | 3 | 4 | 3 | 3 | 2 | 1 | 1 | 1 | 1 |
| Total operating expenses | 45 | 16 | 14 | 6 | 4 | 3 | 1 | 1 | 1 | 1 |
| Operating income | (45) | (16) | (14) | (6) | (4) | (3) | (1) | (1) | (1) | (1) |
| Interest expense | 0 | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (5) | (1) | (6) | (2) | (5) | (1) | 2 | 4 | (2) | (1) |
| Income tax expense | – | – | – | – | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (50) | (17) | (20) | (8) | (9) | (3) | 2 | 4 | (4) | (2) |
| Net income to common shareholders | (48) | (14) | (20) | (7) | (8) | (3) | 2 | 4 | (4) | (2) |